{"entity":{"id":"nct07429266","kind":"trial","name":"INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)","aka":[],"tldr":"A phase 3 trial of Sapablursen in myeloproliferative neoplasms, run by Ono Pharmaceutical Co., Ltd., now recruiting.","summary":"INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV) is a phase 3 interventional study registered as NCT07429266 by Ono Pharmaceutical Co., Ltd., with 250 participants planned, started 2026-05-25 and due to reach its primary completion in 2028-09. Interventions recorded: Sapablursen and Placebo.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07429266","url":"https://clinicaltrials.gov/study/NCT07429266"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["deciphera"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07429266","phase":"3","setting":"A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera","sponsor":"Ono Pharmaceutical Co., Ltd.","enrolled":250,"outcomes":[]},"route":"/trials/nct07429266/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"company":[{"id":"deciphera","kind":"company","name":"Deciphera Pharmaceuticals (Ono)","route":"/companies/deciphera/"}]}}